Additionally, these overexpression models can be applied to further explore ANXA1’s potential as a therapeutic target for diabetes, and to determine whether β cells exposed to glucotoxicity can maintain sufficient insulin production in the presence of elevated ANXA1 levels. Here, ANXA1 is linked to diabetes mellitus.